Search

Displaying results 3451 - 3460 of 10000 in total
  1. Drug

    Pirbuterol

    go.drugbank.com/drugs/DB01291
    ApprovedWithdrawn

    in a concentration between 10-50%. … While it is recognized that beta-2 adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta-2 receptors in the human heart, existing

  2. Drug

    Calcitonin gene-related peptide

    go.drugbank.com/drugs/DB06379
    Investigational

    In particular, it is a potent endogenous vasodilator. … As a potential drug, it has demonstrated in preclinical studies a profile that could make it an ideal anti-asthmatic drug candidate with bronchodilatory, bronchoprotecting and anti-inflammatory properties

  3. Drug

    Ripasudil

    go.drugbank.com/drugs/DB13165
    Investigational

    Ripasudil is a well tolerated medication that is used when other drugs have been proven to be non-effective or cannot be administered. … It was first approved for treatment in Japan in September 2014. This medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec.

  4. Drug

    Ezogabine

    go.drugbank.com/drugs/DB04953
    ApprovedWithdrawn

    FDA approved in June 10, 2011 under the name of ezogabine. … It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures

  5. Drug

    RESP301

    go.drugbank.com/drugs/DB16497
    Investigational

    complications in surgical patients at risk of COVID-19. … It was studied in community patients at risk of viral infections, including SARS-CoV-2, in a terminated trial (NCT04858451) and adults with rifampicin-susceptible pulmonary tuberculosis in a recruiting

  6. Drug

    Andexanet alfa

    go.drugbank.com/drugs/DB14562
    Approved

    It displayed high affinity (0.53–1.53 nmol/L) to apixaban, betrixaban, edoxaban and rivaroxaban [A35518]. … Its pharmacokinetic properties are not reported to be affected by factor Xa inhibitors [A35518].

  7. Drug

    Dasiglucagon

    go.drugbank.com/drugs/DB15226
    Approved

    Although it tends to be more common in type 1 diabetes mellitus, occurring in about 22% to 46% of patients annually, about 7% to 25% of patients with type 2 diabetes mellitus treated with insulin experience … It is available as a subcutaneous injection marketed as ZEGALOGUE.

  8. Drug

    Hemoglobin

    go.drugbank.com/drugs/DB04945
    ApprovedInvestigationalWithdrawn

    It consists primarily of globin and heme.

  9. Drug

    Asparaginase Escherichia coli

    go.drugbank.com/drugs/DB00023
    ApprovedInvestigational

    Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia … It is available as intramuscular or intravenous injections.

    Synonyms: Asparaginase (E. coli), E. coli Asparaginase
  10. Drug

    Atractylodes lancea root oil

    go.drugbank.com/drugs/DB14338
    Approved

    It is not an approved drug.

    Mixtures: OHUI White Extreme Illuminating Pact No.10, OHUI White Extreme Illuminating Pact No.10